Skip to main content
Journal cover image

Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF).

Publication ,  Journal Article
Vinereanu, D; Al-Khalidi, HR; Rao, MP; He, W; Lopes, RD; Bahit, CM; Ciobanu, AO; Fox, KA; Pokorney, SD; Xian, Y; Jiang, J; Kamath, DY; Huo, Y ...
Published in: Am Heart J
October 2017

UNLABELLED: Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide. However, there are few contemporary comparative data on AF from middle-income countries. METHODS: Baseline characteristics of the IMPACT-AF trial were analyzed to assess regional differences in presentation and antithrombotic treatment of AF from 5 middle-income countries (Argentina, Brazil, China, India, and Romania) and factors associated with antithrombotic treatment prescription. RESULTS: IMPACT-AF enrolled 2281 patients (69 ± 11 years, 47% women) at 48 sites. Overall, 66% of patients were on anticoagulation at baseline, ranging from 38% in China to 91% in Brazil. The top 3 reasons for not prescribing an anticoagulant were patient preference/refusal (26%); concomitant antiplatelet therapy (15%); and risks outweighing the benefits, as assessed by the physician (13%). In a multivariable model, the most significant factors associated with prescription of oral anticoagulants were no prior major bleeding (odds ratio [OR] = 4.34; 95% CI = 2.22-8.33), no alcohol abuse (OR = 2.27; 95% CI = 1.12-4.55), and history of rheumatic valvular heart disease (OR = 2.10; 95% CI = 1.36-3.26), with a strong predictive accuracy (c statistic = 0.85), whereas the most significant factors associated with prescription of a combination of oral anticoagulants and antiplatelet drugs were prior coronary revascularization (OR = 5.10; 95% CI = 2.88-9.05), prior myocardial infarction (OR = 2.24; 95% CI = 1.38-3.63), and no alcohol abuse (OR = 2.22; 95% CI = 1.11-4.55), with a good predictive accuracy (c statistic = 0.76). CONCLUSIONS: IMPACT-AF provides contemporary data from 5 middle-income countries regarding antithrombotic treatment of AF. Lack of prior major bleeding and coronary revascularization were the most important factors associated with prescription of oral anticoagulants and their combination with antiplatelet drugs, respectively.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

October 2017

Volume

192

Start / End Page

38 / 47

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Risk Factors
  • Retrospective Studies
  • Registries
  • Middle Aged
  • Male
  • Humans
  • Follow-Up Studies
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vinereanu, D., Al-Khalidi, H. R., Rao, M. P., He, W., Lopes, R. D., Bahit, C. M., … Granger, C. B. (2017). Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). Am Heart J, 192, 38–47. https://doi.org/10.1016/j.ahj.2017.07.004
Vinereanu, Dragos, Hussein R. Al-Khalidi, Meena P. Rao, Wensheng He, Renato D. Lopes, Cecilia M. Bahit, Andrea O. Ciobanu, et al. “Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF).Am Heart J 192 (October 2017): 38–47. https://doi.org/10.1016/j.ahj.2017.07.004.
Vinereanu D, Al-Khalidi HR, Rao MP, He W, Lopes RD, Bahit CM, Ciobanu AO, Fox KA, Pokorney SD, Xian Y, Jiang J, Kamath DY, Berwanger O, Tajer C, Huo Y, Xavier D, Granger CB. Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). Am Heart J. 2017 Oct;192:38–47.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

October 2017

Volume

192

Start / End Page

38 / 47

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Risk Factors
  • Retrospective Studies
  • Registries
  • Middle Aged
  • Male
  • Humans
  • Follow-Up Studies
  • Female